STNE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
STNE is not a good buy right now for an impatient investor. Despite solid fundamental momentum (2025/Q3 growth) and bullish-leaning options positioning, the near-term technical setup is weakening (MACD still positive but contracting, price recently sold off, and pattern-based odds point to downside over the next week/month). I would HOLD/avoid new buys until price reclaims ~16.97 (R1) with strength or pulls back closer to ~15.75 (pivot) and stabilizes.
Trend/price action: The stock is under short-term pressure (regular session -3.47% with additional post-market weakness) and sits near the pivot area (Pivot 15.753) with overhead resistance at R1 16.966 and R2 17.715. Momentum: MACD histogram is positive (0.221) but contracting, signaling bullish momentum is fading rather than accelerating. RSI(6) at ~54 is neutral—no oversold bounce signal. Moving averages are converging, typically a “decision point” that often resolves into a directional move; combined with the selloff, this tilts to a cautious/soft-bearish near-term view. Quant/pattern read: Similar candlestick-pattern analysis implies ~-9.14% next week and ~-8.64% next month, reinforcing that timing is unfavorable for a buy now.
Intellectia Proprietary Trading Signals
Strong recent operating momentum in 2025/Q3 (revenue +16.47% YoY, net income +30.96% YoY, EPS +21.91% YoY) supports the longer-term bull case. Options open interest skew is notably call-heavy (bullish positioning).
No fresh news catalysts in the past week to reverse sentiment. Near-term technicals show fading momentum (MACD contracting) alongside a sharp down day, and pattern-based probabilities point to downside risk over the next week/month. Options trading activity is light versus recent averages, suggesting weaker near-term conviction.
Latest reported quarter: 2025/Q3. Revenue grew to 3,566,790,000 (+16.47% YoY). Net income rose to 706,774,000 (+30.96% YoY) and EPS increased to 2.17 (+21.91% YoY). Gross margin expanded to 75.71 (+1.75% YoY). Overall: accelerating profitability vs revenue growth and improving margins—fundamentals are constructive.
Recent Street trend is modestly less bullish: multiple price target cuts and one downgrade. (2026-01-27) Goldman Sachs cut PT to $19 from $22 (kept Buy). (2026-01-28) UBS cut PT to $19.50 from $20 (kept Buy). (2026-01-28) Grupo Santander downgraded to Neutral from Outperform with a $21 PT. Wall Street pros: Pros—still maintains Buy ratings from major banks and targets remain above the current ~$16 area. Cons—targets are being revised downward and at least one firm stepped to Neutral, implying tempered confidence in near-term upside.
